Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Role of hepatocyte nuclear factor 4-alpha in gastrointestinal and liver diseases.

Yeh MM, Bosch DE, Daoud SS.

World J Gastroenterol. 2019 Aug 14;25(30):4074-4091. doi: 10.3748/wjg.v25.i30.4074. Review.

2.

Genomic variants link to hepatitis C racial disparities.

Yeh MM, Boukhar S, Roberts B, Dasgupta N, Daoud SS.

Oncotarget. 2017 Aug 1;8(35):59455-59475. doi: 10.18632/oncotarget.19755. eCollection 2017 Aug 29.

3.

Design, Implementation, and Assessment Approaches Within a Pharmacogenomics Course.

Remsberg CM, Bray BS, Wright SK, Ashmore J, Kabasenche W, Wang S, Lazarus P, Daoud SS.

Am J Pharm Educ. 2017 Feb 25;81(1):11. doi: 10.5688/ajpe81111.

4.

Multidisciplinary perspective of hepatocellular carcinoma: A Pacific Northwest experience.

Yeh MM, Yeung RS, Apisarnthanarax S, Bhattacharya R, Cuevas C, Harris WP, Hon TL, Padia SA, Park JO, Riggle KM, Daoud SS.

World J Hepatol. 2015 Jun 18;7(11):1460-83. doi: 10.4254/wjh.v7.i11.1460. Review.

5.

Methylation of multiple genes in hepatitis C virus associated hepatocellular carcinoma.

Zekri AR, Bahnasy AA, Shoeab FE, Mohamed WS, El-Dahshan DH, Ali FT, Sabry GM, Dasgupta N, Daoud SS.

J Adv Res. 2014 Jan;5(1):27-40. doi: 10.1016/j.jare.2012.11.002. Epub 2013 Jan 26.

6.

Quantitative proteomic analysis in HCV-induced HCC reveals sets of proteins with potential significance for racial disparity.

Dillon ST, Bhasin MK, Feng X, Koh DW, Daoud SS.

J Transl Med. 2013 Oct 1;11:239. doi: 10.1186/1479-5876-11-239.

7.

Characterization of chronic HCV infection-induced apoptosis.

Zekri AR, Bahnassy AA, Hafez MM, Hassan ZK, Kamel M, Loutfy SA, Sherif GM, El-Zayadi AR, Daoud SS.

Comp Hepatol. 2011 Jul 23;10(1):4. doi: 10.1186/1476-5926-10-4.

8.

Serum levels of β-catenin as a potential marker for genotype 4/hepatitis C-associated hepatocellular carcinoma.

Zekri AR, Bahnassy AA, Alam El-Din HM, Morsy HM, Shaarawy S, Moharram NZ, Daoud SS.

Oncol Rep. 2011 Oct;26(4):825-31. doi: 10.3892/or.2011.1355. Epub 2011 Jun 21.

PMID:
21701780
9.

PRIMA-1 induces apoptosis by inhibiting JNK signaling but promoting the activation of Bax.

Wang T, Lee K, Rehman A, Daoud SS.

Biochem Biophys Res Commun. 2007 Jan 5;352(1):203-12. Epub 2006 Nov 9.

PMID:
17113036
10.

Expression proteomics to p53 mutation reactivation with PRIMA-1 in breast cancer cells.

Lee K, Wang T, Paszczynski AJ, Daoud SS.

Biochem Biophys Res Commun. 2006 Oct 27;349(3):1117-24. Epub 2006 Sep 5.

PMID:
16970918
11.

Proteomic identification of heat shock protein 90 as a candidate target for p53 mutation reactivation by PRIMA-1 in breast cancer cells.

Rehman A, Chahal MS, Tang X, Bruce JE, Pommier Y, Daoud SS.

Breast Cancer Res. 2005;7(5):R765-74. Epub 2005 Jul 27.

12.
13.

Impact of p53 knockout and topotecan treatment on gene expression profiles in human colon carcinoma cells: a pharmacogenomic study.

Daoud SS, Munson PJ, Reinhold W, Young L, Prabhu VV, Yu Q, LaRose J, Kohn KW, Weinstein JN, Pommier Y.

Cancer Res. 2003 Jun 1;63(11):2782-93.

14.

p53 expression, growth, and spontaneous metastasis of the human GI 101 breast carcinoma in athymic nude mice.

Daoud SS, Leathers CW, Hurst JM.

J Exp Ther Oncol. 2002 Mar-Apr;2(2):121-7.

PMID:
12415628
16.

UCN-01 dose-dependent inhibition of normal hyperproliferative cells in mice.

Redkar AA, Meadows GG, Daoud SS.

Int J Oncol. 2001 Jul;19(1):193-9.

PMID:
11408942
17.
18.

Enhancement of camptothecin-induced cytotoxicity with UCN-01 in breast cancer cells: abrogation of S/G(2) arrest.

Jones CB, Clements MK, Wasi S, Daoud SS.

Cancer Chemother Pharmacol. 2000;45(3):252-8.

PMID:
10663644
19.

Antiangiogenic potential of camptothecin and topotecan.

Clements MK, Jones CB, Cumming M, Daoud SS.

Cancer Chemother Pharmacol. 1999;44(5):411-6.

PMID:
10501915
20.

Sensitivity to camptothecin of human breast carcinoma and normal endothelial cells.

Jones CB, Clements MK, Wasi S, Daoud SS.

Cancer Chemother Pharmacol. 1997;40(6):475-83.

PMID:
9332461
21.
22.
23.

Antitumor effect of liposome-incorporated camptothecin in human malignant xenografts.

Daoud SS, Fetouh MI, Giovanella BC.

Anticancer Drugs. 1995 Feb;6(1):83-93.

PMID:
7756688
25.
26.

Cell membranes as targets for anti-cancer drug action.

Daoud SS.

Anticancer Drugs. 1992 Oct;3(5):443-53. Review.

PMID:
1450437
27.

Synergistic cytotoxic actions of cisplatin and liposomal valinomycin on human ovarian carcinoma cells.

Daoud SS, Forde NH.

Cancer Chemother Pharmacol. 1991;28(5):370-6.

PMID:
1914081
29.
30.
31.

Renal handling of adriamycin.

Daoud SS, Huang KC.

Prog Clin Biol Res. 1988;258:161-71.

PMID:
3380821

Supplemental Content

Loading ...
Support Center